Drug intelligence / Profile preview

nab-paclitaxel + tobemstomig

Development stage: Unknown
Lead developer: Roche
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules, Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

nab-paclitaxel + tobemstomig is an investigational combination therapy consisting of nab-paclitaxel, a nanoparticle albumin-bound formulation of the chemotherapy agent paclitaxel, and tobemstomig, a novel immunotherapy. Nab-paclitaxel acts as an antineoplastic agent by stabilizing microtubules and inhibiting cell division in cancer cells. Tobemstomig is a bispecific monoclonal antibody targeting PD-1 and TIM-3 immune checkpoints, designed to enhance anti-tumor immune responses by blocking inhibitory signals on T cells. This combination aims to leverage the cytotoxic effects of chemotherapy with the immune activation provided by checkpoint inhibition for synergistic anti-cancer activity.

Other names: RG6139RG-6139RG 6139RO7121661RO-7121661RO 7121661

Targets

PDCD1 (Programmed cell death protein 1 receptor)TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on nab-paclitaxel + tobemstomig.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on nab-paclitaxel + tobemstomig.

Explore the full profile